Fennec CFO granted 1,191 common shares

Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share.

Accepted by SEC EDGAR 03/03/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share. A footnote explains these shares were released from restrictions on awards originally granted on 3/31/2023 and 5/16/2024. Following this transaction, Andrade directly owns 243,584 common shares.

Insider Trade Summary

Grant/Award: 1,191 shares

Grant/Award 1 txn

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common shares	1,191	$0.00	$0.00

Holdings After Transaction: Common shares — 243,584 shares (Direct)

Holdings Before and After: Common shares, 242,393 to 243,584 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did FENC report for its CFO Robert Andrade?

Fennec Pharmaceuticals reported that CFO Robert Andrade acquired 1,191 common shares through a grant or award at $0.00 per share. The shares came from previously granted awards whose restrictions lapsed, increasing his directly held stake in the company.

How many FENC shares does CFO Robert Andrade own after this Form 4?

After this transaction, CFO Robert Andrade directly owns 243,584 Fennec Pharmaceuticals common shares. This reflects the addition of 1,191 shares released from restrictions on earlier awards granted in March 2023 and May 2024 under his compensation arrangements.

Was the FENC CFO’s Form 4 transaction a market purchase or a grant?

The transaction was a grant or award acquisition, not a market purchase. The 1,191 common shares were released from restrictions on prior equity awards, and the Form 4 shows a transaction price of $0.00 per share for this acquisition.

What does the footnote in Robert Andrade’s FENC Form 4 explain?

The footnote states that the reported 1,191 shares represent shares released from restriction from awards granted on March 31, 2023 and May 16, 2024. It clarifies the shares are vesting-related, rather than new open-market buying or selling activity.

Does the FENC Form 4 show any share sales by the CFO?

The Form 4 does not report any sales by the CFO. It only shows an acquisition of 1,191 common shares through a grant or award with a reported price of $0.00 per share, increasing his directly held ownership to 243,584 common shares.

What type of security is involved in the FENC CFO’s Form 4 filing?

The filing involves Fennec Pharmaceuticals common shares. The Chief Financial Officer acquired 1,191 common shares as part of an equity award vesting, bringing his total direct holdings to 243,584 common shares after the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NC 27709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	02/28/2026		A		1,191	A	$0	243,584	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024.

	/s/ Robert Andrade	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.